Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 36Neoplasms 8HER2-positive Breast Cancer 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Salivary Gland Neoplasms 2Pathologic Complete Response 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2HER2-positive Early Breast Cancer 2Endometrial Neoplasms 2Colonic Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Resectable HER2-positive Breast Cancer 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoproliferative Disorders 1Lung Neoplasms 1Liver Neoplasms 1Hemangiosarcoma 1Heart Failure 1

Interventions

pyrotinib 1pertuzumab 1disitamab vedotin 1Trastuzumab 1RC48 antibody 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Metastatic Breast Cancer × pertuzumab × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡